eXoZymes, Inc.
NASDAQ:EXOZBiotechnology
+$1.06 today
- Market cap
- $51.42M
- Beta
- 2.66
- P/E (TTM)
- -6.5
- EPS (TTM)
- -$1.14
Volume 0.01M
Average 0.01M
EXOZ Income Before Tax
Profit after all operating and non-operating items but before income tax.
eXoZymes, Inc.NASDAQ: EXOZ
Income Before Tax · Q1 FY2026 · quarter ended Mar 2026
Income before tax remains negative
Q1 FY2026 income before tax was -$2.37M, compared with -$1.86M a year earlier. Trailing-twelve-month income before tax was -$9.78M.
Context
- Income before tax grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly income before tax holds near -$2.37M or moves back toward the trailing-twelve-month quarterly average of -$2.44M.
Sources:Income StatementText generated from reported figures; not investment advice.
Income Before Tax history
USD · from the income statement
- Latest · FY2025
- (9.26M) USD
- Year-over-year change
- -58.1%
| Period | Period end | Income Before Tax | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (9.26M) | -58.1% |
| FY2024 | 2024-12-31 | (5.86M) | -193.6% |
| FY2023 | 2023-12-31 | (2M) | -49.8% |
| FY2022 | 2022-12-31 | (1.33M) | -10.2% |
| FY2021 | 2021-12-31 | (1.21M) | — |
Income Before Tax vs competitors
How EXOZ compares with its peers on the latest reported figures
- Peers report in different currencies, so income before tax is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -45.7% is the 6th highest of 7, against a peer median of -15.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
EXOZeXoZymes, Inc. | LTM Mar 2026 | -$9.78M USD | -45.7% | — | — |
| FY2025 | -$18.43M USD | -10.1% | — | — | |
| LTM Mar 2026 | -$19.58M USD | +41.2% | — | — | |
| LTM Mar 2026 | -$21.76M USD | -35.5% | — | — | |
| LTM Mar 2026 | -CA$35.35M CAD | -20.1% | — | — | |
| LTM Mar 2026 | -$47.38M USD | +39.3% | — | — | |
| LTM Mar 2026 | -$342.56M USD | -319.3% | — | 4571.1% | |
| Peer median (excluding EXOZ) | — | -15.1% | — | 4571.1% | |
Competitors are the stored peer set for EXOZ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 59.41K | 147.75K | 0 | 267.38K | 0 |
| Gross Profit | (59.41K) | (147.75K) | 0 | (267.38K) | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 454.45K | 348.08K | 527.48K | 1.87M | 3.71M |
| Selling, General & Admin | 778.99K | 836.83K | 1.34M | 3.8M | 5.91M |
| Operating Expenses | 1.23M | 1.18M | 1.8M | 5.66M | 9.72M |
| Depreciation & Amortization | 59.41K | 147.75K | 196.94K | 267.38K | 287.96K |
| EBITDA | (1.15M) | (1.18M) | (1.8M) | (5.59M) | (8.98M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (1.29M) | (1.33M) | (1.8M) | (5.93M) | (9.72M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 98 | 100 | 77.61K | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 83.74K | 98 | (199.9K) | 70.77K | 452.53K |
| Income Before Tax | (1.21M) | (1.33M) | (2M) | (5.86M) | (9.26M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 63.56K | 42.27K | 0 | (105.21K) |
| Net Income | (1.21M) | (1.4M) | (2.04M) | (5.86M) | (9.16M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.15) | (0.17) | (0.25) | (0.72) | (1.09) |
| EPS (Diluted) | (0.15) | (0.17) | (0.25) | (0.72) | (1.09) |
| Weighted Avg Shares | 8.13M | 8.13M | 8.13M | 8.13M | 8.38M |
| Weighted Avg Shares (Diluted) | 8.13M | 8.13M | 8.13M | 8.13M | 8.38M |
eXoZymes, Inc.
NASDAQ:EXOZ
Intrinsic Alpha fair value
Locked
Current Price
$5.54
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.